Table 4 Polymer concentrations and clinical characteristics: liver and/or lung disease
From: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
Patients heterozygous for the Z allele and untreated patients with the Pi*ZZ genotype (n = 49) | ||||
|---|---|---|---|---|
No COPD and LSM < 6 kPa (n = 23) | COPD and LSM < 6 kPa (n = 18) | No COPD and LSM ≥ 6 kPa (n = 6) | COPD and LSM ≥ 6 kPa (n = 2) | |
AAT (mg/dL) | 61.1 (33.2) | 39.4 (22.8) | 47.5 (38.3) | 76.1 (56.4) |
AAT polymers (µg/mL) | 14.4 (8) | 26.5 (14.4) | 34.0 (21.6) | 47.5 (32.8) |
AAT polymers (%) | 4.7 (5.4) | 9.8 (7.5) | 11.2 (7.9) | 10.8 (12.2) |
Untreated patients with Pi*ZZ genotype (n = 21) | ||||
|---|---|---|---|---|
No COPD and LSM < 6 kPa (n = 6) | COPD and LSM < 6 kPa (n = 10) | No COPD and LSM ≥ 6 kPa (n = 4) | COPD and LSM ≥ 6 kPa (n = 1) | |
AAT (mg/dL) | 19.4 (3.8) | 22.4 (3.6) | 27.4 (7.6) | 36 (–) |
AAT polymers (µg/mL) | 25.3 (2.9) | 32.3 (14.9) | 44.7 (17.8) | 70.3 (–) |
AAT polymers (%) | 13.2 (1.6) | 14.5 (6.5) | 16 (3.3) | 19.4 (–) |